In yesterday’s Wall Street session, Rain Therapeutics Inc. (NASDAQ:RAIN) shares traded at $9.49, up 8.46% from the previous session.
8 analysts cover Rain Therapeutics Inc. (NASDAQ:RAIN), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $29.00 and a low of $12.00, we find $16.50. Given the previous closing price of $8.75, this indicates a potential upside of 88.57 percent. RAIN stock price is now 23.24% away from the 50-day moving average and 68.86% away from the 200-day moving average. The market capitalization of the company currently stands at $317.54M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
The stock has received a hold rating from 0 analysts and a buy rating from 8. Brokers who have rated the stock have averaged $18.63 as their price target over the next twelve months.
With the price target of $10, H.C. Wainwright recently initiated with Buy rating for Rain Therapeutics Inc. (NASDAQ: RAIN). On April 01, 2022, Oppenheimer recently initiated its ‘Outperform’ rating on the stock quoting a target price of $15, while ‘Goldman’ rates the stock as ‘Neutral’.
In other news, BERGER FRANKLIN M, Director bought 77,000 shares of the company’s stock on Nov 22. The stock was bought for $636,790 at an average price of $8.27. Upon completion of the transaction, the Director now directly owns 1,005,207 shares in the company, valued at $9.54 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 21, Director BERGER FRANKLIN M bought 45,000 shares of the business’s stock. A total of $351,000 was incurred on buying the stock at an average price of $7.80. This leaves the insider owning 928,207 shares of the company worth $8.81 million. Insiders disposed of 59,618 shares of company stock worth roughly $0.57 million over the past 1 year. A total of 6.00% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in RAIN stock. A new stake in Rain Therapeutics Inc. shares was purchased by JACOBS LEVY EQUITY MANAGEMENT, INC during the first quarter worth $215,000. PARAMETRIC PORTFOLIO ASSOCIATES LLC invested $147,000 in shares of RAIN during the first quarter. In the first quarter, AMALGAMATED FINANCIAL CORP. acquired a new stake in Rain Therapeutics Inc. valued at approximately $22,000. SARGENT BICKHAM LAGUDIS LLC acquired a new stake in RAIN for approximately $22,000. UBS GROUP AG purchased a new stake in RAIN valued at around $16,000 in the second quarter. In total, there are 68 active investors with 61.80% ownership of the company’s stock.
On Friday morning Rain Therapeutics Inc. (NASDAQ: RAIN) stock kicked off with the opening price of $8.80. During the past 12 months, Rain Therapeutics Inc. has had a low of $2.15 and a high of $14.48. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 7.20, and a quick ratio of 7.20. The fifty day moving average price for RAIN is $7.78 and a two-hundred day moving average price translates $5.64 for the stock.
The latest earnings results from Rain Therapeutics Inc. (NASDAQ: RAIN) was released for Jun, 2022.
Rain Therapeutics Inc.(RAIN) Company Profile
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
